Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Aprea Therapeutics, Inc.

APRE · Nasdaq · CIK 0001781983 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

8 Form 4 transaction lines observed in the same window
0 sales · 8 option, withholding, award, gift or other lines

Last qualifying purchase2026-01-30 · Gilad Oren · $25.0K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesNone
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Grissinger MichaelDirector
○
Gruia GabrielaDirector
○
Peters RichardDirector
○
HENNEMAN JOHN B IIIDirector
○
BIZZARI JEAN-PIERREDirector
○
Duey MarcDirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 2 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-01-30 · Gilad Oren.

Recent Form 4 activity

4Purchases
0Sales
10Other Form 4 lines
14SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-27.5%
3M
-16.9%
6M
-13.8%
12M
-59.3%

Volatility & liquidity

Volatility
87.3%
Beta
1.63
Avg daily value
USD 165,605

Valuation

Market cap
USD 7.6M
P/E
—

Fundamentals

Profit margin
0.0%
ROE
-101.3%
Industry
Biotechnology

Market data

Price data up to: 2026-10-07 · Price source: OpenBB/yfinance · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · From Yahoo Finance: Market cap, Profit margin · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
508,841
Previous report
574,605
Avg daily volume
207,556
Days to cover
2.5

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-01-30Hamill John P.Purchase (P)Common Stock5,700USD 0.89USD 5,073SEC filing ↗
2026-01-30Gilad OrenPurchase (P)Common Stock28,100USD 0.89USD 25,009SEC filing ↗
2025-12-10Hamill John P.Purchase (P)Common Stock5,000USD 1.17USD 5,850SEC filing ↗
2025-12-10Duey MarcPurchase (P)Common Stock21,459USD 1.17USD 25,107SEC filing ↗
2025-04-03Gilad OrenPurchase (P)Common Stock5,500USD 1.84USD 10,110SEC filing ↗
2024-10-23Gilad OrenPurchase (P)Common Stock500USD 3.92USD 1,960SEC filing ↗
2024-10-16Duey MarcPurchase (P)Common Stock30,000USD 4.39USD 131,700SEC filing ↗
2024-10-15Gilad OrenPurchase (P)Common Stock250USD 2.90USD 725SEC filing ↗
2024-10-14Duey MarcPurchase (P)Common Stock190USD 2.58USD 490SEC filing ↗
2024-10-14Gilad OrenPurchase (P)Common Stock1,000USD 2.59USD 2,590SEC filing ↗
2024-10-11Hamill John P.Purchase (P)Common Stock50USD 2.46USD 123SEC filing ↗
2024-10-11Seizinger Bernd R.Purchase (P)Common Stock10,000USD 2.68USD 26,800SEC filing ↗
2024-10-10Hamill John P.Purchase (P)Common Stock450USD 2.61USD 1,174SEC filing ↗
2024-10-10Gilad OrenPurchase (P)Common Stock150USD 2.54USD 381SEC filing ↗
2024-03-13Seizinger Bernd R.Purchase (P)Common Stock6,860USD 7.29USD 50,009SEC filing ↗

Form 4 evidence

14 transaction lines in the latest 365-day window; 156 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-16Seizinger Bernd R.Award / grant (A)Common Stock3,135USD 0.00USD 0SEC filing ↗
2026-06-16Peters RichardAward / grant (A)Common Stock3,135USD 0.00USD 0SEC filing ↗
2026-06-16Pamukcu RifatAward / grant (A)Common Stock3,135USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (14 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-16Seizinger Bernd R.Award / grant (A)Common Stock3,135USD 0.00USD 0SEC filing ↗
2026-06-16Peters RichardAward / grant (A)Common Stock3,135USD 0.00USD 0SEC filing ↗
2026-06-16Pamukcu RifatAward / grant (A)Common Stock3,135USD 0.00USD 0SEC filing ↗
2026-06-16HENNEMAN JOHN B IIIAward / grant (A)Common Stock3,135USD 0.00USD 0SEC filing ↗
2026-06-16Gruia GabrielaAward / grant (A)Common Stock3,135USD 0.00USD 0SEC filing ↗
2026-06-16Grissinger MichaelAward / grant (A)Common Stock3,135USD 0.00USD 0SEC filing ↗
2026-06-16Duey MarcAward / grant (A)Common Stock3,135USD 0.00USD 0SEC filing ↗
2026-06-16BIZZARI JEAN-PIERREAward / grant (A)Common Stock3,135USD 0.00USD 0SEC filing ↗
2026-03-12Hamill John P.Award / grant (A)Common Stock10,095USD 0.00USD 0SEC filing ↗
2026-03-12Gilad OrenAward / grant (A)Common Stock20,175USD 0.00USD 0SEC filing ↗
2026-01-30Hamill John P.Purchase (P)Common Stock5,700USD 0.89USD 5,073SEC filing ↗
2026-01-30Gilad OrenPurchase (P)Common Stock28,100USD 0.89USD 25,009SEC filing ↗
2025-12-10Hamill John P.Purchase (P)Common Stock5,000USD 1.17USD 5,850SEC filing ↗
2025-12-10Duey MarcPurchase (P)Common Stock21,459USD 1.17USD 25,107SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerAPRE
CIK0001781983
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history156 transaction lines from 2020-04-09 to 2026-06-16
23 P purchase lines · 28 S sale lines · 105 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.